| [1] |
Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a US multicenter, prospective study. Hepatology, 2010, 52:2065-2076.
|
| [2] |
Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci, 2011, 56:958-976.
|
| [3] |
Bjornsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology, 2010, 51:2040-2048.
|
| [4] |
Stine JG, Chalasani N. Chronic liver injury induced by drugs: a systematic review. Liver Int, 2015, 35:2343-2353.
|
| [5] |
Agarwal VK, McHutchison JG, Hoofnagle JH. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol, 2010, 8:463-470.
|
| [6] |
Hisamochi A, Kage M, Ide T, et al. An analysis of drug-induced liver injury, which showed histological findings similar to autoimmune hepatitis. J Gastroenterol, 2016, 51:597-607.
|
| [7] |
Homberg JC, Andre C, Abuaf N. A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. Clin Exp Immunol, 1984, 55:561-570.
|
| [8] |
Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology, 2011, 54:931-939.
|
| [9] |
Kuzu UB, Oztas E, Turhan N, et al. Clinical and histological features of idiosyncratic liver injury: Dilemma in diagnosis of autoimmune hepatitis. Hepatol Res, 2016, 46:277-291.
|
| [10] |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol, 2015, 63:971-1004.
|
| [11] |
Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology, 2010, 138:2246-2259.
|
| [12] |
Voskuhl R. Sex differences in autoimmune diseases. Biol Sex Differ, 2011, 2:1.
|
| [13] |
Roberts WC. Safety of fenofibrate--US and worldwide experience. Cardiology, 1989, 76:169-179.
|
| [14] |
Parra JL, Reddy KR. Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis, 2003, 7:415-433.
|
| [15] |
Dumortier J, Slim R, Chevallier M, et al. Acute severe fibrosing hepatitis associated with ciprofibrate treatment. Gastroenterol Clin Biol, 1999, 23:1399-1400.
|
| [16] |
Chatrenet P, Regimbeau C, Ramain JP, et al. Chronic active cirrhogenic hepatitis induced by fenofibrate. Gastroenterol Clin Biol, 1993, 17:612-613.
|
| [17] |
Bernard PH, Lamouliatte H, Le Bail B, et al. Chronic active hepatitis associated with antinuclear antibodies induced by fenofibrate. Gastroenterol Clin Biol, 1994, 18:1048-1049.
|
| [18] |
Russo MW, Hoofnagle JH, Gu J, et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology, 2014, 60:679-686.
|
| [19] |
Alla V, Abraham J, Siddiqui J, et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol, 2006, 40:757-761.
|
| [20] |
Mansilla-Tinoco R, Harland SJ, Ryan PJ, et al. Hydralazine, antinuclear antibodies, and the lupus syndrome. Br Med J (Clin Res Ed), 1982, 284:936-939.
|
| [21] |
Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 2010, 363:711-723.
|
| [22] |
Kahler KC, Hauschild A. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges, 2011, 9:277-286.
|
| [23] |
Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 2010, 363:711-723.
|
| [24] |
Cheng R, Cooper A, Kench J, et al. Ipilimumab-induced toxicities and the gastroenterologist. J Gastroenterol Hepatol, 2015, 30:657-666.
|
| [25] |
Kleiner DE, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci, 2012, 57:2233-2240.
|
| [26] |
Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol, 2012, 30:2691-2697.
|
| [27] |
Ahmed T, Pandey R, Shah B, et al. Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. BMJ Case Rep, 2015, 2015.
|
| [28] |
Chmiel KD, Suan D, Liddle C, et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol, 2011, 29:e237-240.
|
| [29] |
Knowles SR, Shapiro L, Shear NH. Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Arch Dermatol, 1996, 132:934-939.
|
| [30] |
Amit G, Cohen P, Ackerman Z. Nitrofurantoin-induced chronic active hepatitis. Isr Med Assoc J, 2002, 4:184-186.
|
| [31] |
Stine JG, Lewis JH. Hepatotoxicity of antibiotics: a review and update for the clinician. Clin Liver Dis, 2013, 17:609-642, ix.
|
| [32] |
Fagrell B, Strandberg I, Wengle B. A nitrofurantoin-induced disorder simulating chronic active hepatitis. A case report. Acta Med Scand, 1976, 199:237-239.
|
| [33] |
Adar T, Mizrahi M, Pappo O, et al. Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol, 2010, 44:e20-22.
|
| [34] |
Mancini S, Amorotti E, Vecchio S, et al. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med, 2010, 5:193-200.
|
| [35] |
Poulin Y, Therien G. Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: case report and literature review. J Cutan Med Surg, 2010, 14:100-104.
|
